AT-012

N/A

Report date: 2025/02/02 20:00:08
NME

Base Information

Drug NameAT-012
Drug Alias NameAT-012ASN3186ASN-3186APL-2302
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUbiquitin carboxyl-terminal hydrolase 1 inhibitors
TargetsUbiquitin carboxyl-terminal hydrolase 1
Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAsieris Pharmaceuticals (USA) Inc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Yahong Pharmaceutical Technology Co LtdAsieris Pharmaceuticals LtdAsieris Pharmaceuticals (USA) Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursOvarian NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A